AML/TMDS与MDS-AML的对比研究

目的 :分析三系病态造血的急性髓系白血病 (AML/TMDS)与骨髓增生异常综合征演变为急性髓系白血病 (MDS AML)的差异。方法 :采用常规形态学和细胞化学染色方法观察患者外周血和骨髓细胞。结果 :AML/TMDS患者血小板计数和外周原始细胞百分率高于MDS AML(P <0 0 5 ,P <0 0 1) ;小巨核细胞和Pseudo pelger异常明显低于MDS AML(P <0 0 5 ,P <0 0 1) ,2组病例MPO染色阳性率基本一致 ,但AML/TMDS患者MPO积分显著高于MDS AML(P <0 0 1)。AML/TMDS患者多核原始红细胞明显低于MDS AML(P <0 0 5 ) ;AML/TMDS与MDS AML患者巨大血小板分别为 2 3 1%和 86 7%。结论 :AML/TMDS与MDS AML白血病克隆不同 ,正确诊断对确定方案、判断疗效及预后有重要意义

Comparative Study on AML/TMDS and MDS-AML

Objective To investigate the distinction between AML/TMDS and MDS AML.Methods Morpholism and cell chemical staining were used to study the periferal blood cells and marrow cells.Results The percentages of platelet and peripheral primitive cells were both higher than those in MDS AML( P <0 05, P <0 01).And percentages of macronuclear cells and Pseudo pelger were lower than those in MDS AML( P <0 05, P <0 01).The positive rates of MPO stain in two cases were roughly concordant,but the MPO score in patients with AML/TMDS was absolutely higher than that of MDS AML( P <0 01).And they had lower number of multinuclear primitive erythrocytes than MDS AML( P <0 05).Percentages of giant platelet in two cases were 23 1% and 86 7% respectively.Conclusions AML/TMDS and MDS AML originate from different leukemia clone.Correct diagnosis is important to determine the treatment scheme,to judge curative effect and prognosis. China J Cancer Prev Treat,2003,10(3):292-293